Development of lipid nanoparticles with nystatin for an antifungal action
DOI:
https://doi.org/10.21814/jus.4677Keywords:
Candida, nystatin, SLN, stability, Carbopol® 940Abstract
Fungal diseases currently affect about a quarter of the population worldwide. Fungi infections caused by Candida albicans have been described as a significant concern to public health. The spectrum of clinical diseases caused by this fungi species range between vulvovaginal candidiasis, oral candidiasis, candidemia and mucositis. The emergence of resistance mechanisms towards antifungal therapy greatly hampers successful management of illness and patient outcome. Nystatin, an antifungal drug, is categorized as a class IV of Biopharmaceutical Classification System, presenting low aqueous solubility and low intestinal permeability. Nowadays, the emerging platform of nanotechnology and lipid nanoparticles, notably solid lipid nanoparticles (SLN), has been subject to growing attention over recent past, owing to the promising properties of vectorization among a substantial variety of pharmaceutical drugs. Due to its hydrophobic proprieties, nystatin was encapsulated in SLN. Thus aiming to understand the relationship between the use of nanosystems and the improvement of the therapeutic effect. The aim of this work was to formulate SLN with nystatin by different methods (high speed homogenization and ultrasonication) with optimization of several parameters and formulation of 2 gels (one of them containing nanoparticles).
Initially, 3 lipids were used: Compritol® 888 ATO, cetyl palmitate and Precirol® ATO 5 and, after the study of several parameters (size, encapsulation efficiency (EE) and polymorphic behaviour of the lipids), Precirol® ATO 5 was chosen as the lipid with the most satisfactory results. The results of the present work showed that the assay method of nystatin was linear, specific and presented repeatability. The average diameter of empty nanoparticles (NPs) and with drug (Precirol-NYS NPs) was, respectively, 306 nm and 260 nm and an EE of 67.8%. Regarding stability, SLN with drug proved to be more stable than SLN without drug. The polymer used for formulation of gels was the polymer commonly known by the trade name Carbopol® 940. The yield of 0.5% Carbopol® gel preparations and 0.5% Carbopol® gel + 10% Precirol-NYS NPs were 87.2% and 91.39%, respectively.
References
F. L. Mayer, D. Wilson, and B. Hube, "Candida albicans pathogenicity mechanisms," Virulence, vol. 4, no. 2, pp. 119-28, Feb 15 2013, doi: 10.4161/viru.22913. DOI: https://doi.org/10.4161/viru.22913
F. Sousa, D. Ferreira, S. Reis, and P. Costa, "Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs from Natural Sources," Pharmaceuticals, vol. 13, no. 9, p. 248, 2020, doi: 10.3390/ph13090248. DOI: https://doi.org/10.3390/ph13090248
J. J. La Clair, "Accessing Nystatin through Mariculture," Molecules, vol. 26, no. 24, Dec 17 2021, doi: 10.3390/molecules26247649. DOI: https://doi.org/10.3390/molecules26247649
F. Offner et al., "Liposomal Nystatin in Patients with Invasive Aspergillosis Refractory to or Intolerant of Amphotericin B," Antimicrobial Agents and Chemotherapy, vol. 48, no. 12, pp. 4808-4812, 2004, doi: 10.1128/aac.48.12.4808-4812.2004. DOI: https://doi.org/10.1128/AAC.48.12.4808-4812.2004
M. M. de Aguiar et al., "Oral sustained release nystatin tablets for the treatment of oral candidiasis: formulation development and validation of UV spectrophotometric analytical methodology for content determination," Drug Dev Ind Pharm, vol. 36, no. 5, pp. 594-600, May 2010, doi: 10.3109/03639040903384729. DOI: https://doi.org/10.3109/03639040903384729
T. P. Day, D. Sil, N. M. Shukla, A. Anbanandam, V. W. Day, and S. A. David, "Imbuing Aqueous Solubility to Amphotericin B and Nystatin with a Vitamin," Molecular Pharmaceutics, vol. 8, no. 1, pp. 297-301, 2011, doi: 10.1021/mp100363f. DOI: https://doi.org/10.1021/mp100363f
L. Kristanc, B. Bozic, S. Z. Jokhadar, M. S. Dolenc, and G. Gomiscek, "The pore-forming action of polyenes: From model membranes to living organisms," Biochim Biophys Acta Biomembr, vol. 1861, no. 2, pp. 418-430, Feb 1 2019, doi: 10.1016/j.bbamem.2018.11.006. DOI: https://doi.org/10.1016/j.bbamem.2018.11.006
D. B. Bylund, S. J. Enna, and S. Elsevier, xPharm : the comprehensive pharmacology reference. Place of publication not identified: Elsevier (in English), 2008.
K. M. Wasan, M. Ramaswamy, S. M. Cassidy, M. Kazemi, F. W. Strobel, and R. L. Thies, "Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma," Antimicrob Agents Chemother, vol. 41, no. 9, pp. 1871-5, Sep 1997, doi: 10.1128/AAC.41.9.1871. DOI: https://doi.org/10.1128/AAC.41.9.1871
R. Blaschke-Hellmessen, U. Pannwitz, and R. Schwarze, "[Intestinal excretion of nystatin during and after oral administration to newborn infants at risk]," Monatsschr Kinderheilkd, vol. 139, no. 2, pp. 89-91, Feb 1991. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/2038352. Zur intestinalen Ausscheidung von Nystatin wahrend und nach oraler Applikation bei Risikoneugeborenen.
T. M. Allen and P. R. Cullis, "Drug delivery systems: entering the mainstream," Science, vol. 303, no. 5665, pp. 1818-22, Mar 19 2004, doi: 10.1126/science.1095833. DOI: https://doi.org/10.1126/science.1095833
M. A. Ferreira et al., "Annatto Oil Loaded Nanostructured Lipid Carriers: A Potential New Treatment for Cutaneous Leishmaniasis," Pharmaceutics, vol. 13, no. 11, p. 1912, 2021, doi: 10.3390/pharmaceutics13111912. DOI: https://doi.org/10.3390/pharmaceutics13111912
A. H. Groll et al., "Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits," Antimicrob Agents Chemother, vol. 44, no. 4, pp. 950-7, Apr 2000, doi: 10.1128/AAC.44.4.950-957.2000. DOI: https://doi.org/10.1128/AAC.44.4.950-957.2000
R. H. Muller, M. Radtke, and S. A. Wissing, "Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations," Adv Drug Deliv Rev, vol. 54 Suppl 1, pp. S131-55, Nov 1 2002, doi: 10.1016/s0169-409x(02)00118-7. DOI: https://doi.org/10.1016/S0169-409X(02)00118-7
M. Uner and G. Yener, "Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives," Int J Nanomedicine, vol. 2, no. 3, pp. 289-300, 2007. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/18019829.
K. Sakeer, H. Al-Zein, I. Hassan, S. Desai, and A. Nokhodchi, "Enhancement of dissolution of nystatin from buccoadhesive tablets containing various surfactants and a solid dispersion formulation," Archives of Pharmacal Research, vol. 33, no. 11, pp. 1771-1779, 2010, doi: 10.1007/s12272-010-1109-1. DOI: https://doi.org/10.1007/s12272-010-1109-1
F. I. Safitri, D. Nawangsari, and D. Febrina, "Overview: Application of Carbopol 940 in Gel," 2021: Atlantis Press, doi: 10.2991/ahsr.k.210127.018. [Online]. Available: https://dx.doi.org/10.2991/ahsr.k.210127.018 DOI: https://doi.org/10.2991/ahsr.k.210127.018
L. H. Samein. Preparation and evaluation of nystatin loaded-solid-lipid nanoparticles for topical delivery, vol. 6, pp. 592-597, 2014.
Y. Wang, Y. Deng, S. Mao, S. Jin, J. Wang, and D. Bi, "Characterization and body distribution of beta-elemene solid lipid nanoparticles (SLN)," Drug Dev Ind Pharm, vol. 31, no. 8, pp. 769-78, Sep 2005, doi: 10.1080/03639040500216329. DOI: https://doi.org/10.1080/03639040500216329
J. M. Llabot, D. A. Allemandi, R. H. Manzo, and M. R. Longhi, "HPLC method for the determination of nystatin in saliva for application in clinical studies," J Pharm Biomed Anal, vol. 45, no. 3, pp. 526-30, Nov 5 2007, doi: 10.1016/j.jpba.2007.06.014. DOI: https://doi.org/10.1016/j.jpba.2007.06.014
C. f. D. Evaluation, Research, U. S. Food, and D. Administration, Reviewer Guidance: Validation of Chromatographic Methods. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, 1994.
A. P. P. Cione, M. J. Liberale, and P. M. d. Silva, "Development and validation of an HPLC method for stability evaluation of nystatin," Brazilian Journal of Pharmaceutical Sciences, vol. 46, 2010. DOI: https://doi.org/10.1590/S1984-82502010000200018
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Cecilia Nascimento, Filipa Sousa, Salette Reis, Paulo Costa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal Uminho Science (JUS) magazine, in order to protect the interests of the authors of the articles and also their own, follows the terms and conditions of "Creative Commons Atribution 4.0 International Public License" whose credit belongs to “Creative Commons” (creativecommons.org).
By agreeing to the terms of this license you are granting us your permission to use your item under the terms and conditions specified in this license.
"By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.
Section 1 – Definitions.
Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.
Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.
Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.
Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.
Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.
Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.
Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.
Licensor means the individual(s) or entity(ies) granting rights under this Public License.
Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.
Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.
You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.
Section 2 – Scope.
License grant.
Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:
- Reproduce and Share the Licensed Material, in whole or in part; and
- Produce, reproduce, and Share Adapted Material.
Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.
Term. The term of this Public License is specified in Section 6(a).
Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a)(4) never produces Adapted Material.
Downstream recipients.
Offer from the Licensor – Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.
No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.
No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).
Other rights.
Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.
Patent and trademark rights are not licensed under this Public License.
To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties.
Section 3 – License Conditions.
Your exercise of the Licensed Rights is expressly made subject to the following conditions.
Attribution.
If You Share the Licensed Material (including in modified form), You must retain the following if it is supplied by the Licensor with the Licensed Material:
- Identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);
- A copyright notice;
- A notice that refers to this Public License;
- A notice that refers to the disclaimer of warranties;
- A URI or hyperlink to the Licensed Material to the extent reasonably practicable;
- Indicate if You modified the Licensed Material and retain an indication of any previous modifications; and
- Indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.
You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.
If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.
If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.
Section 4 – Sui Generis Database Rights.
Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:
- For the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database;
- If You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material;
- You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.
For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.
Section 5 – Disclaimer of Warranties and Limitation of Liability.
Unless otherwise separately undertaken by the Licensor, to the extent possible, the Licensor offers the Licensed Material as-is and as-available, and makes no representations or warranties of any kind concerning the Licensed Material, whether express, implied, statutory, or other. This includes, without limitation, warranties of title, merchantability, fitness for a particular purpose, non-infringement, absence of latent or other defects, accuracy, or the presence or absence of errors, whether or not known or discoverable. Where disclaimers of warranties are not allowed in full or in part, this disclaimer may not apply to You.
To the extent possible, in no event will the Licensor be liable to You on any legal theory (including, without limitation, negligence) or otherwise for any direct, special, indirect, incidental, consequential, punitive, exemplary, or other losses, costs, expenses, or damages arising out of this Public License or use of the Licensed Material, even if the Licensor has been advised of the possibility of such losses, costs, expenses, or damages. Where a limitation of liability is not allowed in full or in part, this limitation may not apply to You.
The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.
Section 6 – Term and Termination.
This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.
Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:
- Automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation;
- Or, upon express reinstatement by the Licensor.
For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.
For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.
Sections 1, 5, 6, 7, and 8 survive termination of this Public License.
Section 7 – Other Terms and Conditions.
The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.
Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.
Section 8 – Interpretation.
For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.
To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.
No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.
Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority."
